OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Picozzi on the Use of SM-88 in Pancreatic Cancer

January 29th 2019

Vincent J. Picozzi, MD, director, Pancreatic Center of Excellence, Virginia Mason Medical Center, discusses the use of SM-88 in pancreatic cancer.

Dr. Mehanna on Implications of the Updated Staging System for HPV+ Head and Neck Cancer

January 29th 2019

Hisham Mehanna, PhD, BMedSc, MBChB, FRCS, chair, Head and Neck Surgery director, Institute of Head and Neck Studies and Education at the School of Cancer Studies, University of Birmingham, discusses the implications of the updated staging system for patients with HPV-positive head and neck cancer.

Dr. Kaplan on the Phase III ECHELON-1 Trial in Hodgkin Lymphoma

January 29th 2019

Lawrence D. Kaplan, MD, clinical professor of medicine, director, Adult Lymphoma Program, Division of Hematology-Oncology, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the results of the phase III ECHELON-1 trial in Hodgkin lymphoma.

Dr. Eyre on Resistance to BTK Inhibition in MCL

January 26th 2019

Toby Eyre, MCBhB, MRCP, consultant hematologist at Oxford University Hospitals NHS Trust, discusses resistance to BTK inhibition in mantle cell lymphoma (MCL).

Dr. Oh Discusses the Differences Between Investigational JAK Inhibitors and Ruxolitinib in MPNs

January 26th 2019

Stephen Oh, MD, PhD, assistant professor of medicine, Division of Hematology, Washington University School of Medicine in St. Louis, Siteman Cancer Center, discusses the differences between investigational JAK inhibitors and ruxolitinib (Jakafi) in the treatment of patients with myeloproliferative neoplasms (MPNs).

Dr. Wright on the Underutilization of Bladder Preservation in Localized Bladder Cancer

January 26th 2019

Jonathan L. Wright, MD, MS, FACS, medical director of the University of Washington Medical Center Urology Clinic, associate professor of Urology at University of Washington, and affiliate investigator at the Fred Hutchinson Cancer Research Center, discusses the underutilization of bladder preservation in patients with localized bladder cancer.

Dr. Shields Discusses Patient Selection Criteria for Adjuvant Therapy in CRC

January 25th 2019

Anthony Shields, MD, PhD, oncologist, Department of Oncology, Molecular Imaging and Diagnostics Program, Karmanos Cancer Institute, discusses patient selection criteria for adjuvant therapy in colorectal cancer (CRC).

Dr. Meeks on the Importance of p53 and Rb1 in Bladder Cancer

January 25th 2019

Joshua J. Meeks, MD, PhD, assistant professor of urology, Northwestern University Feinberg School of Medicine, discusses the importance of p53 and Rb1 in bladder cancer.

Dr. English on an Investigational Antibody-Drug Conjugate in Ovarian Cancer

January 25th 2019

Diana P. English, MD, a gynecologic oncologist at Stanford Hospital and Clinics, discusses an investigational antibody-drug conjugate (ADC) in ovarian cancer.

Dr. Hurvitz Discusses Role of Pertuzumab in HER2+ Breast Cancer

January 25th 2019

Sara A. Hurvitz, MD, director of the Breast Oncology Program, medical director of the Clinical Research Unit, University of California, Los Angeles Jonsson Comprehensive Cancer Center, discusses the role of pertuzumab in HER2-positive breast cancer.

Dr. Kris Discusses Role of Antiangiogenesis in Lung Cancer

January 25th 2019

Mark G. Kris, MD, medical oncologist, William and Joy Ruane Chair in Thoracic Oncology, Memorial Sloan Kettering Cancer Center, discusses the role of antiangiogenesis in the treatment of patients with lung cancer.

Dr. Cohen Discusses Promise of Immunotherapy in Head and Neck Cancer

January 25th 2019

Ezra Cohen, MD, associate director, Moores Cancer Center at the University of California, San Diego, discusses the promise of immunotherapy in the treatment of patients with head and neck cancer.

Dr. Horowitz on Frontline Strategies in Newly Diagnosed Ovarian Cancer

January 24th 2019

Neil Horowitz, MD, director of Clinical Research in Gynecologic Oncology, assistant professor of Obstetrics, Gynecology and Reproductive Biology, Harvard Medical School, Dana-Farber Cancer Institute, discusses frontline strategies in the treatment of patients with newly diagnosed advanced ovarian cancer.

Dr. Kasi on the Rising Incidence of CRC

January 24th 2019

Pashtoon M. Kasi, MD, MBBS, MS, an assistant professor of Oncology and senior associate consultant in the Division of Hematology/Oncology, Mayo Clinic, discusses the rising incidence of colorectal cancer (CRC).

Dr. Steinberg on the Standard of Care in Non-Muscle Invasive Bladder Cancer

January 24th 2019

Gary D. Steinberg, MD, director, Urologic Oncology, The University of Chicago Medicine, discusses the standard of care in patients with non-muscle invasive bladder cancer (NMIBC).

Dr. Clark Discusses Need for Biomarkers in RCC

January 24th 2019

Peter Clark, MD, professor of medicine and chair of urology, Levine Cancer Institute, Atrium Health, discusses the need for biomarkers in renal cell carcinoma.

Dr. Dorff on Choosing Between Therapies in Nonmetastatic CRPC

January 24th 2019

Tanya B. Dorff, MD, associate clinical professor, Department of Medical Oncology and Therapeutics Research, head, Genitourinary Cancers Program, City of Hope, discusses choosing between therapies in nonmetastatic castration-resistant prostate cancer.

Dr. Camidge Discusses Treatment of Patients With ALK+ NSCLC

January 24th 2019

D. Ross Camidge, MD, PhD, director of thoracic oncology, University of Colorado, discusses optimal treatment strategies for patients with ALK-mutated non–small cell lung cancer.

Dr. Goetz on Survival Data With CDK4/6 Inhibitors in Breast Cancer

January 23rd 2019

Matthew P. Goetz, MD, chair of the Breast Cancer Disease-Oriented Group and co-leader of the Women’s Cancer Center at the Mayo Clinic, discusses survival data with CDK4/6 inhibitors in patients with hormone receptor-positive breast cancer.

Dr. Kujtan on Patient Preferences in the Treatment of NSCLC

January 23rd 2019

Lara Kujtan, MD, assistant professor at the University of Missouri–Kansas City School of Medicine, discusses the importance of patient preferences in the treatment of oncogene-driven non-small cell lung cancer (NSCLC).

x